Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells.
Sensebé Luc,Tarte Karin,Galipeau Jacques,Krampera Mauro,Martin Ivan,Phinney Donald G,Shi Yufang,null null
DOI: https://doi.org/10.1016/j.stem.2011.12.005
IF: 23.9
2012-01-01
Cell Stem Cell
Abstract:In their recent article entitled “Large-Scale Analysis Reveals Acquisition of Lineage-Specific Chromosomal Aberrations in Human Adult Stem Cells,” Ben-David and colleagues conclude that human adult mesenchymal stromal cells (MSCs) have a 4% probability of acquiring chromosomal abnormalities (Ben-David et al., 2011Ben-David U. Mayshar Y. Benvenisty N. Cell Stem Cell. 2011; 9: 97-102Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar). Moreover, the authors propose, based on their analysis, that transplantation of adult stem cells may result in tumor formation, an assertion that calls into question the safety of MSC-based cell therapy. Their study is based on a comprehensive evaluation of acquired chromosomal aberrations performed using gene expression profiles for a large series of human stem cells from different origins (neural stem cells, MSCs, and pluripotent stem cells). However, in our opinion some of the points within the reported results and in the presented conclusions should have been discussed in a more balanced way, particularly those that relate to adult MSCs, which are already being used for clinical trials looking at immunoregulation and tissue repair. Overall, Ben-David et al. identified MSC genetic instability in 4 studies out of the 22 that they analyzed. In one of them (GSE18934_GSM469130; Ben-David et al.'s Table S1), the MSCs presenting chromosomal aberrations were derived from fetal liver, and thus should not be considered postnatal stem cells of adult origin. In another (GSE9520; Ben-David et al.'s Table S1), Ben-David et al. report three different MSC preparations displaying the same monosomy 6q appearing at the beginning of the second passage at day 2, but later disappearing at day 7. This culture development is not discussed by Ben-David et al., but would seem to be at odds with their general interpretation that “in MSCs chromosomal aberrations can take over the culture in as few as seven passages” and that “multipotent stem cells are prone to acquire advantageous chromosomal aberrations that enable them to rapidly outgrow the normal cell population.” On the contrary, these results suggest a selective pressure against monosomy 6q. The findings of Ben-David et al. that only 4% of examined MSC lines carry a detectable genomic abnormality is in agreement with those of Tarte et al., 2010Tarte K. Gaillard J. Lataillade J.J. Fouillard L. Becker M. Mossafa H. Tchirkov A. Rouard H. Henry C. Splingard M. et al.Société Française de Greffe de Moelle et Thérapie CellulaireBlood. 2010; 115: 1549-1553Crossref PubMed Scopus (372) Google Scholar, who reported a longitudinal study of 20 clinical-grade MSC preparations obtained using two distinct and well-defined culture conditions and showed that the cells do display some chromosomal abnormalities, i.e. trisomies of chromosomes 5, 8, and/or 20, as detected using conventional karyotype and FISH analysis. However, as for the monosomy 6q, these trisomies did not appear to confer any selective mitogenic advantage in vitro and disappeared rapidly after the second or the third passage. Finally, all MSC batches reached senescence without recurrence of these chromosomal abnormalities and no cell transformation could be documented either in vitro or in immunocompromised mice. All these observations argue against the idea that acquisition of lineage-specific chromosomal aberrations confers a growth advantage in human adult stem cells. Finally, Ben-David et al. cite certain potentially misleading articles to support their arguments. The potential transformation of MSCs in culture reported by Røsland et al., 2009Røsland G.V. Svendsen A. Torsvik A. Sobala E. McCormack E. Immervoll H. Mysliwietz J. Tonn J.C. Goldbrunner R. Lønning P.E. et al.Cancer Res. 2009; 69: 5331-5339Crossref PubMed Scopus (519) Google Scholar was related to a cross-contamination by various cancer cell lines (Torsvik et al., 2010Torsvik A. Røsland G.V. Svendsen A. Molven A. Immervoll H. McCormack E. Lønning P.E. Primon M. Sobala E. Tonn J.C. et al.Cancer Res. 2010; 70: 6393-6396Crossref PubMed Scopus (237) Google Scholar). The same problem occurred in a study performed on adipose tissue-derived MSCs that was subsequently retracted (de la Fuente et al., 2010, addressed by Garcia et al., 2010Garcia S. Bernad A. Martín M.C. Cigudosa J.C. Garcia-Castro J. de la Fuente R. Exp. Cell Res. 2010; 316: 1648-1650Crossref PubMed Scopus (137) Google Scholar), underlining the absolute requirement to validate, prior to scientific publication, that the cells analyzed at the end of a culture period actually derive from those used to initiate the culture. It also seems misleading to state that “transplantation of human adult stem cells may result in tumor formation” by referencing an article in which cells used were fetal neural cells and not adult cells (Amariglio et al., 2009Amariglio N. Hirshberg A. Scheithauer B.W. Cohen Y. Loewenthal R. Trakhtenbrot L. Paz N. Koren-Michowitz M. Waldman D. Leider-Trejo L. et al.PLoS Med. 2009; 6: e1000029Crossref PubMed Scopus (739) Google Scholar), and another article showing tumor formation only in immunocompromised mice injected with NSCs derived from an olfactory bulb adjacent to meningioma (Casalbore et al., 2009Casalbore P. Budoni M. Ricci-Vitiani L. Cenciarelli C. Petrucci G. Milazzo L. Montano N. Tabolacci E. Maira G. Larocca L.M. Pallini R. PLoS ONE. 2009; 4: e4434Crossref PubMed Scopus (43) Google Scholar). In conclusion, we would argue that genomic stability of cultured adult stem cells and MSCs in particular is robust and not as significant a source of concern as was suggested by Ben-David et al., 2011Ben-David U. Mayshar Y. Benvenisty N. Cell Stem Cell. 2011; 9: 97-102Abstract Full Text Full Text PDF PubMed Scopus (191) Google Scholar. Thus, we would suggest that a more balanced view of the fundamental issue of genetic stability of adult stem cells should be provided to all parties with an interest in this field, including researchers, physicians, and regulatory authorities.